Eli Lilly Statistics
Total Valuation
Eli Lilly has a market cap or net worth of $710.32 billion. The enterprise value is $745.25 billion.
| Market Cap | 710.32B |
| Enterprise Value | 745.25B |
Important Dates
The next confirmed earnings date is Thursday, August 7, 2025, before market open.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | May 16, 2025 |
Share Statistics
Eli Lilly has 897.74 million shares outstanding. The number of shares has decreased by -0.02% in one year.
| Current Share Class | 897.74M |
| Shares Outstanding | 897.74M |
| Shares Change (YoY) | -0.02% |
| Shares Change (QoQ) | -0.28% |
| Owned by Insiders (%) | 0.16% |
| Owned by Institutions (%) | 88.69% |
| Float | 895.50M |
Valuation Ratios
The trailing PE ratio is 64.38 and the forward PE ratio is 31.71. Eli Lilly's PEG ratio is 0.98.
| PE Ratio | 64.38 |
| Forward PE | 31.71 |
| PS Ratio | 14.53 |
| Forward PS | 11.26 |
| PB Ratio | 47.56 |
| P/TBV Ratio | 178.38 |
| P/FCF Ratio | 190.10 |
| P/OCF Ratio | 76.24 |
| PEG Ratio | 0.98 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 33.87, with an EV/FCF ratio of 199.45.
| EV / Earnings | 67.10 |
| EV / Sales | 15.21 |
| EV / EBITDA | 33.87 |
| EV / EBIT | 36.94 |
| EV / FCF | 199.45 |
Financial Position
The company has a current ratio of 1.37, with a Debt / Equity ratio of 2.44.
| Current Ratio | 1.37 |
| Quick Ratio | 0.57 |
| Debt / Equity | 2.44 |
| Debt / EBITDA | 1.74 |
| Debt / FCF | 10.33 |
| Interest Coverage | 23.88 |
Financial Efficiency
Return on equity (ROE) is 77.28% and return on invested capital (ROIC) is 26.92%.
| Return on Equity (ROE) | 77.28% |
| Return on Assets (ROA) | 16.45% |
| Return on Invested Capital (ROIC) | 26.92% |
| Return on Capital Employed (ROCE) | 34.01% |
| Revenue Per Employee | $1.04M |
| Profits Per Employee | $236,306 |
| Employee Count | 47,000 |
| Asset Turnover | 0.64 |
| Inventory Turnover | 1.16 |
Taxes
In the past 12 months, Eli Lilly has paid $2.49 billion in taxes.
| Income Tax | 2.49B |
| Effective Tax Rate | 18.34% |
Stock Price Statistics
The stock price has decreased by -9.93% in the last 52 weeks. The beta is 0.39, so Eli Lilly's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | -9.93% |
| 50-Day Moving Average | 775.78 |
| 200-Day Moving Average | 825.38 |
| Relative Strength Index (RSI) | 54.56 |
| Average Volume (20 Days) | 3,303,547 |
Short Selling Information
The latest short interest is 8.03 million, so 0.89% of the outstanding shares have been sold short.
| Short Interest | 8.03M |
| Short Previous Month | 7.35M |
| Short % of Shares Out | 0.89% |
| Short % of Float | 0.90% |
| Short Ratio (days to cover) | 1.58 |
Income Statement
In the last 12 months, Eli Lilly had revenue of $49.00 billion and earned $11.11 billion in profits. Earnings per share was $12.29.
| Revenue | 49.00B |
| Gross Profit | 40.03B |
| Operating Income | 20.17B |
| Pretax Income | n/a |
| Net Income | 11.11B |
| EBITDA | 22.00B |
| EBIT | 20.17B |
| Earnings Per Share (EPS) | $12.29 |
Balance Sheet
The company has $3.22 billion in cash and $38.60 billion in debt, giving a net cash position of -$34.92 billion or -$38.90 per share.
| Cash & Cash Equivalents | 3.22B |
| Total Debt | 38.60B |
| Net Cash | -34.92B |
| Net Cash Per Share | -$38.90 |
| Equity (Book Value) | 15.85B |
| Book Value Per Share | 16.64 |
| Working Capital | 11.19B |
Cash Flow
In the last 12 months, operating cash flow was $9.32 billion and capital expenditures -$5.58 billion, giving a free cash flow of $3.74 billion.
| Operating Cash Flow | 9.32B |
| Capital Expenditures | -5.58B |
| Free Cash Flow | 3.74B |
| FCF Per Share | $4.16 |
Margins
Gross margin is 81.70%, with operating and profit margins of 41.17% and 22.66%.
| Gross Margin | 81.70% |
| Operating Margin | 41.17% |
| Pretax Margin | 27.75% |
| Profit Margin | 22.66% |
| EBITDA Margin | 44.90% |
| EBIT Margin | 41.17% |
| FCF Margin | 7.63% |
Dividends & Yields
This stock pays an annual dividend of $6.00, which amounts to a dividend yield of 0.76%.
| Dividend Per Share | $6.00 |
| Dividend Yield | 0.76% |
| Dividend Growth (YoY) | 15.23% |
| Years of Dividend Growth | 10 |
| Payout Ratio | 48.82% |
| Buyback Yield | 0.02% |
| Shareholder Yield | 0.78% |
| Earnings Yield | 1.56% |
| FCF Yield | 0.53% |
Analyst Forecast
The average price target for Eli Lilly is $1,014.22, which is 28.18% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $1,014.22 |
| Price Target Difference | 28.18% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (5Y) | 17.73% |
| EPS Growth Forecast (5Y) | 33.03% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on October 16, 1997. It was a forward split with a ratio of 2:1.
| Last Split Date | Oct 16, 1997 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Eli Lilly has an Altman Z-Score of 7.85 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.85 |
| Piotroski F-Score | 6 |